Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH is high as a result of recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.
United States, EU5, Japan
Key Drugs Covered:
Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis/Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, esuberaprost, bardoxolone methyl, inhaled dry powder treprostinil, INOpulse
Key Companies Mentioned:
Actelion · United Therapeutics · Bayer Healthcare · GlaxoSmithKline · Gilead Sciences · Pfizer · Arena Pharmaceuticals · Mannkind Corporation · Bellerophon Therapeutics · Liquidia Technologies · Reata Pharmaceuticals
Already a Client? Log in to access this report.
David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.
Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31 st , 2015. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office. Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.